Effects of 1‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine and 1 ‐Methyl‐4‐Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes

Journal of Neurochemistry

Volumn 54, Issue 4, 1990, Pages 1295-1301

  Scotcher, Kevin P ^a   Irwin, Ian ^a   DeLanney, Louis E ^a   Langston, J William ^a   Di Monte, Donato ^a  

^a CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

ATP; l Methyl 4 phenylpyridinium ion; l Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Synaptosomes

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE TRIPHOSPHATE;

AGED; ANIMAL CELL; ARTICLE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNAPTOSOME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATE; ANIMAL; ANTIMYCIN A; BRAIN; IODOACETATES; IODOACETIC ACID; IONS; MALE; MICE; MICE, INBRED C57BL; ROTENONE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SYNAPTOSOMES;

ANIMALIA;

EID: 0025329856     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.1990.tb01962.x     Document Type: Article

References (41)

1. Mitochondrial transmembrane potential and pH gradient during anoxia
2. Is the dopamine uptake system required for MPTP to induce neurotoxicity in the primate brain
3. A rapid method for the preparation of relatively pure metabolically competent synaptosomes from rat brain
4. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
5. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
6. The metabolism of rat brain mitochondria
7. Chronic parkinsonism secondary to intravenous injection of meperidine analogs
8. A dopaminergic cell line variant resistant to the neurotoxin l‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
9. +) cause rapid ATP depletion in isolated hepatocytes
10. Role of l‐methyl‐4‐phenylpyridinium ion formation and accumulation in l‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine toxicity to isolated rat hepatocytes
11. Fructose prevents l‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced ATP depletion and toxicity in isolated hepatocytes
12. Electron transport system of yeast. III Preparation and properties of cytochrome oxidase
13. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice
14. Isolation and partial characterization of rat brain synaptic plasma membranes
15. + neurotoxicity are spread beyond dopaminergic terminals
16. + in the substantia nigra: a key to neurotoxicity
17. + concentrations and neurotoxicity
18. Parkinsonism‐inducing neurotoxin, l‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine: uptake of the metabolite N‐methyl‐4‐phenylpyridine by dopamine neurons explains selective toxicity
19. MPTP: current concepts and controversies
20. Chronic parkinsonism in humans due to a product of meperidine synthesis
21. l‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine causes selective damage to the zona compacta of the substantia nigra in the squirrel monkey
22. +): identification of a metabolite of MPTP, a toxin selective to the substantia nigra
23. Firefly luciferase assay for ATP production by mitochondria
24. 2+ and mitochondrial membrane potential preceding cell death in hepatocytes
25. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons
26. Protein measurement with the Folin phenol reagent
27. Intraneuronal generation of a pyridinium metabolite may cause drug‐induced parkinsonism
28. Prevention of the nigrostriatal toxicity of l‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine by inhibitors of 3,4‐dihydroxyphenylethylamine transport
29. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP
30. Isolation and use of liver cells
31. Inhibition of NADH‐linked oxidation in brain mitochondria by l‐methyl‐4‐phenylpyridine, a metabolite of the neurotoxin l‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
32. Energy‐dependent uptake of N‐methyl‐4‐phenylpyridinium, the neurotoxic metabolite of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine, by mitochondria
33. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism
34. Dopamine uptake blockers protect against the dopamine depleting effect of l‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) in the mouse striatum
35. The catecholamine uptake blocker nomifensine protects against MPTP‐induced parkinsonism in monkeys
36. CNS glucose metabolic changes in the stages of the MPTP primate model of Parkinson's disease
37. MPTP and MPTP analogs induced cell death in cultured rat hepatocytes involving the formation of pyridinium metabolites
38. Free radical induced changes in the surface morphology of isolated hepatocytes
39. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease
40. Pharmacological interference with the neurotoxic action of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse
41. Distinct monoamine oxidase A and B populations in primate brain